Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - 103 Studies Found
Terminated |
: Abatacept in ANCA Associated Vasculitis : ANCA-associated Vasculitis : 2007-06-01 : Drug: Abatacept (Orencia) 500mg for patients under 60kg 75 |
Recruiting |
: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis : ANCA-Associated Vasculitis : 2016-12-11 :
|
Terminated |
: Defining Immune Tolerance in ANCA-associated Vasculitis (AAV) : ANCA-Associated Vasculitis : 2013-08-29 : Procedure: Venipuncture for blood sample collection Analysis samples from the blood sample collection at |
Withdrawn |
: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab : Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis : 2010-12-13 :
|
Terminated |
: The Clinical Efficacy of DFPP in Patients With AAGN : Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis : 2014-06-03 :
|
Withdrawn |
: Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens : Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis : 2011-01-10 :
|
Completed |
: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis : ANCA-associated Vasculitis : 2014-08-19 :
|
Active, not recruiting |
: CMV Modulation of the Immune System in ANCA-associated Vasculitis :
: 2012-06-29 : Drug: Valaciclovir 2g q.d.s. orally for 6 months (dose adjusted according to renal function) |
Completed |
: Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis :
: 2015-05-12 |
Recruiting |
: Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis :
: 2015-05-12 |